Sensei Biotherapeutics Completes $200M Financing and Narrows 2025 Net Loss to $21.1M
Sensei Biotherapeutics closed a $200 million private placement and acquired Faeth Therapeutics to support PIKTOR’s Phase 2 endometrial and planned Phase 1b breast cancer trials, expecting topline data by late 2026. Full-year 2025 cash fell to $21.2 million as net loss narrowed to $21.1 million from $30.2 million in 2024.
1. Acquisition and Financing
Sensei Biotherapeutics acquired Faeth Therapeutics and raised $200 million in private financing to support advancement of PIKTOR, its all-oral PI3K-alpha and dual mTORC1/2 inhibitor. The funding, together with existing cash, is earmarked for topline data from the Phase 2 endometrial cancer trial and initiation of the Phase 1b breast cancer study.
2. Clinical Development Plans
PIKTOR targets multiple nodes of the PI3K/AKT/mTOR pathway, with topline results from Study FTH-PIK-201 expected in advanced endometrial cancer by year-end 2026. A Phase 1b trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101) is slated to begin in 2026, with potential expansion into ovarian and lung cancer indications.
3. 2025 Financial Performance
Sensei ended 2025 with $21.2 million in cash and marketable securities, down from $41.3 million at year-end 2024, following financing and clinical investments. The company reduced R&D expenses to $11.0 million and G&A costs to $11.3 million, narrowing its net loss to $21.1 million, or $16.72 per share, compared with a $30.2 million loss in 2024.